Ulla Westin

Ulla Westin

Auto-generated profile, based on publicly available information

Ulla Westin

Department of Otolaryngology and Head and Neck Surgery, University Hospital of Malmö, University of Lund, Sweden

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
UWUlrika Westin
Ulrika Westin
EPElena Piras
Elena Piras
BJBjörn Jansson
Björn Jansson
UBUlrika Bergström
Ulrika Bergström
MDMaria Dahlin
Maria Dahlin
EBErik Björk
Erik Björk

27 January 2016 in Respiratory Research
Verified
Journal Article
Open access
PDF file
THTerese Hylander
Terese Hylander
OLOlivia Larsson
Olivia Larsson
UPUlla Petersson-Westin
Ulla Petersson-Westin
MEMia Eriksson
Mia Eriksson
SGSusanna Lumlien Georén
Susanna Lumlien Georén
LCLars Olaf Cardell
Lars Olaf Cardell
Allergen-specific immunotherapy represents the only disease-modifying treatment for allergic diseases. We and others have previously demonstrated that intralymphatic immunotherapy (ILIT), a less time-consuming alternative to conventional subcutaneous immunotherapy (SCIT), is safe and effective. However, this has recently been disputed. The aim of this study was therefore to expand our previous trial, further assessing the safety and efficacy of ILIT. Thirty-six patients with pollen-induced rhinoconjunctivitis were randomised to receive three intralymphatic inguinal injections of active allergen (1000 SQ-U birch- or grass-pollen) or placebo. Clinical effects, safety and circulating immunological markers were assessed before, 4 weeks after treatment and at the end of the consecutive pollen season. No moderate or severe reactions were recorded following ILIT. Patients receiving active ILIT experienced a significant improvement in self-recorded seasonal allergic symptoms, as compared to placebo (p = 0.05). In a subgroup of these patients (“improved”), a reduction in nasal symptoms following nasal allergen provocation was also demonstrated. No changes in total IgE or IgG4 were found. However, the affinity of allergen specific IgG4 following active treatment was significantly increased, as compared to non-improved patients (p = 0.04). This could be correlated with clinical improvement, on an individual level. This double-blinded placebo-controlled study confirms that ILIT is a safe and effective treatment for pollen-induced rhinoconjunctivitis, markedly reducing seasonal allergic symptoms. EudraCT: 2009-016815-39

25 February 2006 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
UWUlrika Espefält Westin
Ulrika Espefält Westin
EBEmma Boström
Emma Boström
JGJohan Gråsjö
Johan Gråsjö
MHMargareta Hammarlund-Udenaes
Margareta Hammarlund-Udenaes
EBErik Björk
Erik Björk

31 January 2005 in Respiratory Research
Verified
Journal Article
Open access
PDF file
INIzabela Nita
Izabela Nita
CHCamilla Hollander
Camilla Hollander
UWUlla Westin
Ulla Westin
SJSabina-Marija Janciauskiene
Sabina-Marija Janciauskiene
Background: α1-antitrypsin (AAT) serves primarily as an inhibitor of the elastin degrading proteases, neutrophil elastase and proteinase 3. There is ample clinical evidence that inherited severe AAT deficiency predisposes to chronic obstructive pulmonary disease. Augmentation therapy for AAT deficiency has been available for many years, but to date no sufficient data exist to demonstrate its efficacy. There is increasing evidence that AAT is able to exert effects other than protease inhibition. We investigated whether Prolastin, a preparation of purified pooled human AAT used for augmentation therapy, exhibits anti-bacterial effects. Methods: Human monocytes and neutrophils were isolated from buffy coats or whole peripheral blood by the Ficoll-Hypaque procedure. Cells were stimulated with lipopolysaccharide (LPS) or zymosan, either alone or in combination with Prolastin, native AAT or polymerised AAT for 18 h, and analysed to determine the release of TNFα, IL-1β and IL-8. At 2-week intervals, seven subjects were submitted to a nasal challenge with sterile saline, LPS (25 μg) and LPS-Prolastin combination. The concentration of IL-8 was analysed in nasal lavages performed before, and 2, 6 and 24 h after the challenge. Results: In vitro, Prolastin showed a concentration-dependent (0.5 to 16 mg/ml) inhibition of endotoxin-stimulated TNFα and IL-1β release from monocytes and IL-8 release from neutrophils. At 8 and 16 mg/ml the inhibitory effects of Prolastin appeared to be maximal for neutrophil IL-8 release (5.3-fold, p < 0.001 compared to zymosan treated cells) and monocyte TNFα and IL-1β release (10.7- and 7.3-fold, p < 0.001, respectively, compared to LPS treated cells). Furthermore, Prolastin (2.5 mg per nostril) significantly inhibited nasal IL-8 release in response to pure LPS challenge. Conclusion: Our data demonstrate for the first time that Prolastin inhibits bacterial endotoxin-induced pro-inflammatory responses in vitro and in vivo, and provide scientific bases to explore new Prolastin-based therapies for individuals with inherited AAT deficiency, but also for other clinical conditions.

29 October 2008 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
CSC. S. Sandström
C. S. Sandström
BOB. Ohlsson
B. Ohlsson
OMO. Melander
O. Melander
UWU. Westin
U. Westin
RMR. Mahadeva
R. Mahadeva
SJS. Janciauskiene
S. Janciauskiene

1 September 2007 in Respiratory Medicine
Verified
Journal Article
Closed access
CHCamilla Hollander
Camilla Hollander
Brigita GradauskieneBrigita Gradauskiene
Brigita Gradauskiene
RSRaimundas Sakalauskas
Raimundas Sakalauskas
UWUlla Westin
Ulla Westin
SJSabina M. Janciauskiene
Sabina M. Janciauskiene